157 related articles for article (PubMed ID: 10482971)
1. Left ventricular hypertrophy predicts outcome of hypertension regardless of the type of ventricular arrhythmia present.
Frimm CD; Trezza B; Gruppi C; Medeiros C; Cúri M; Krieger E
J Hum Hypertens; 1999 Sep; 13(9):617-23. PubMed ID: 10482971
[TBL] [Abstract][Full Text] [Related]
2. [Arrhythmogenicity in left ventricular hypertrophy in mild to moderate arterial hypertension].
Franchi F; Michelucci A; Padeletti L; Monopoli A; Fabbri G; Cersosimo RM; Mezzani A
G Ital Cardiol; 1992 Aug; 22(8):905-18. PubMed ID: 1478391
[TBL] [Abstract][Full Text] [Related]
3. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy.
Bikkina M; Larson MG; Levy D
J Am Coll Cardiol; 1993 Oct; 22(4):1111-6. PubMed ID: 8409049
[TBL] [Abstract][Full Text] [Related]
4. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Oikarinen L; Nieminen MS; Viitasalo M; Toivonen L; Jern S; Dahlöf B; Devereux RB; Okin PM;
Hypertension; 2004 May; 43(5):1029-34. PubMed ID: 15037560
[TBL] [Abstract][Full Text] [Related]
5. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.
Paoletti E; De Nicola L; Gabbai FB; Chiodini P; Ravera M; Pieracci L; Marre S; Cassottana P; Lucà S; Vettoretti S; Borrelli S; Conte G; Minutolo R
Clin J Am Soc Nephrol; 2016 Feb; 11(2):271-9. PubMed ID: 26668021
[TBL] [Abstract][Full Text] [Related]
6. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
Bang CN; Soliman EZ; Simpson LM; Davis BR; Devereux RB; Okin PM;
Am J Hypertens; 2017 Sep; 30(9):914-922. PubMed ID: 28430947
[TBL] [Abstract][Full Text] [Related]
7. [The role of hypertrophy and left ventricular function on the occurrence of ventricular arrhythmias in arterial hypertension].
Frimm Cde C; Gruppi C; de Moraes AV; Silva HB; Krieger EM; Bellotti G; Pileggi F
Arq Bras Cardiol; 1994 Aug; 63(2):91-6. PubMed ID: 7661717
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure variability and multiple organ damage in primary hypertension.
Leoncini G; Viazzi F; Storace G; Deferrari G; Pontremoli R
J Hum Hypertens; 2013 Nov; 27(11):663-70. PubMed ID: 23739158
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Cicala S; de Simone G; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2008 Apr; 26(4):806-12. PubMed ID: 18327092
[TBL] [Abstract][Full Text] [Related]
10. Electrocardiographic left ventricular hypertrophy criteria and ambulatory blood pressure monitoring parameters in adults.
Gómez-Marcos MA; Recio-Rodríguez JI; Patino-Alonso MC; Agudo-Conde C; Fernandez-Alonso C; Martinez Vizcaino V; Cantera CM; Guenaga-Saenz N; González-Viejo N; García-Ortiz L;
Am J Hypertens; 2014 Mar; 27(3):355-62. PubMed ID: 24190901
[TBL] [Abstract][Full Text] [Related]
11. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Okin PM; Kjeldsen SE; Julius S; Hille DA; Dahlöf B; Edelman JM; Devereux RB
Eur Heart J; 2010 Sep; 31(18):2271-9. PubMed ID: 20601389
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of electrocardiographic Tpeak-Tend interval in the general and in the hypertensive population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study.
Bombelli M; Maloberti A; Raina L; Facchetti R; Boggioni I; Pizzala DP; Cuspidi C; Mancia G; Grassi G
J Hypertens; 2016 Sep; 34(9):1823-30. PubMed ID: 27348518
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
Verma A; Meris A; Skali H; Ghali JK; Arnold JM; Bourgoun M; Velazquez EJ; McMurray JJ; Kober L; Pfeffer MA; Califf RM; Solomon SD
JACC Cardiovasc Imaging; 2008 Sep; 1(5):582-91. PubMed ID: 19356485
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and predictors of left ventricular hypertrophy in patients with hypertension and normal electrocardiogram.
Nardi E; Palermo A; Mulè G; Cusimano P; Cerasola G; Rini GB
Eur J Prev Cardiol; 2013 Oct; 20(5):854-61. PubMed ID: 22556375
[TBL] [Abstract][Full Text] [Related]
16. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events.
Rieck ÅE; Cramariuc D; Boman K; Gohlke-Bärwolf C; Staal EM; Lønnebakken MT; Rossebø AB; Gerdts E
Hypertension; 2012 Jul; 60(1):90-7. PubMed ID: 22647889
[TBL] [Abstract][Full Text] [Related]
17. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
[TBL] [Abstract][Full Text] [Related]
18. Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension.
Tomiyama M; Horio T; Kamide K; Nakamura S; Yoshihara F; Nakata H; Nakahama H; Kawano Y
J Hum Hypertens; 2007 Mar; 21(3):212-9. PubMed ID: 17167525
[TBL] [Abstract][Full Text] [Related]
19. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
[TBL] [Abstract][Full Text] [Related]
20. Left Ventricular Structure and Risk of Cardiovascular Events: A Framingham Heart Study Cardiac Magnetic Resonance Study.
Tsao CW; Gona PN; Salton CJ; Chuang ML; Levy D; Manning WJ; O'Donnell CJ
J Am Heart Assoc; 2015 Sep; 4(9):e002188. PubMed ID: 26374295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
